BridgeBio: Strong Start For Attruby
Portfolio Pulse from
BridgeBio's Attruby has achieved over 1,000 unique prescriptions in the US within three months of FDA approval. The company anticipates more patients by year-end, though growth may slow due to Alnylam's Amvuttra. BridgeBio's pipeline includes three pivotal trials reporting data in the next year.
February 20, 2025 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BridgeBio's Attruby has over 1,000 prescriptions in the US within three months of FDA approval. The company expects more patients by year-end, but growth may slow due to Alnylam's Amvuttra. Three pivotal trials are set to report data within the next year.
The strong start of Attruby with over 1,000 prescriptions indicates positive market reception, likely boosting BridgeBio's stock. However, the potential slowdown due to Alnylam's Amvuttra could moderate this impact. The upcoming trial data could further influence stock performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90